raxatrigine
Vixotrigine, formerly known as raxatrigine, is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain. It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued. — Wikipedia
Clinical trial activity
20 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2008 (NCT00908154)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
SMILES
NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1- Mol. weight
- 314.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVixotrigine ↗
- ChEMBLCHEMBL3544913 ↗
Also known as
- biib074
- biib074
- cnv1014802
- cnv1014802
- cnv-1014802
- cnv-1014802
- gsk1014802
- gsk1014802
- gsk1014802
- raxatrigine
- raxatrigine
- raxatrigine
- vixotrigine
- vixotrigine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04106050 | Phase 1 | Nov 29, 2019 | Biogen |
| NCT03637387 | Phase 3 | Nov 29, 2018 | Biogen |
| NCT03339336 | Phase 2 | Apr 16, 2018 | Biogen |
| NCT03324685 | Phase 1 | Nov 11, 2017 | Biogen |
| NCT03385525 | Phase 1 | Sep 12, 2017 | Biogen |
| NCT03070132 | Phase 3 | Jul 1, 2017 | Biogen |
| NCT02957617 | Phase 2 | Feb 10, 2017 | Convergence Pharmaceuticals |
| NCT02951221 | Phase 1 | Dec 1, 2016 | Biogen |
| NCT02935608 | Phase 2 | Oct 31, 2016 | Convergence Pharmaceuticals |
| NCT02917187 | Phase 2 | Sep 1, 2016 | Convergence Pharmaceuticals |
| NCT02831517 | Phase 1 | Aug 1, 2016 | Biogen |
| NCT02751905 | Phase 1 | Apr 1, 2016 | Biogen |
| NCT02698267 | Phase 1 | Feb 1, 2016 | Biogen |
| NCT02551497 | Phase 1 | Apr 30, 2015 | Convergence Pharmaceuticals |
| NCT02359344 | Phase 1 | Feb 1, 2015 | Convergence Pharmaceuticals, Parexel |
| NCT01540630 | Phase 2 | Mar 1, 2012 | Convergence Pharmaceuticals, University of London |
| NCT01561027 | Phase 2 | Apr 1, 2011 | Bragee Medect AB, Stockholm, Sweden, Convergence Pharmaceuticals |
| NCT00955396 | Phase 1 | Jul 1, 2009 | GlaxoSmithKline |
| NCT00964288 | Phase 1 | Jul 1, 2009 | GlaxoSmithKline |
| NCT00908154 | Phase 1 | May 1, 2008 | GlaxoSmithKline |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 10 | 10 | 3 | 2016 |
| Convergence Pharmaceuticals | For profit | 7 | 7 | 2 | 2011 |
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2008 |
| Bragee Medect AB, Stockholm, Sweden | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Parexel | For profit | 1 | 0 | 1 | 2015 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2012 |